alexa Atovaquone: A Valuable Therapeutic Option in Toxoplasma
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Atovaquone: A Valuable Therapeutic Option in Toxoplasma Retinochoroiditis

Alexander Reis1,2*, Christophe Valmaggia3, Tamer Tandogan1, Karoline Rippel1and Olja Girmann1
1Reis Augenklinik, Liechtenstein
2Augenklinik, Universität Freiburg, Germany
3Augenklinik, Kantonsspital St. Gallen, Switzerland
Corresponding Author : Prof. Dr. Alexander Reis
Reis Augenklinik, Eschnerstrasse 4
FL 9487 Bendern; Germany
Tel: 00423 399 0424
E-mail: [email protected]
Received: January 14, 2015; Accepted: April 15, 2015; Published: April 20, 2015
Citation: Reis A, Valmaggia C, Tandogan T, Rippel K, Girmann O (2015) Atovaquone: A Valuable Therapeutic Option in Toxoplasma Retinochoroiditis. J Clin Exp Ophthalmol 6:418. doi:10.4172/2155-9570.1000418
Copyright: ©2015 Reis A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Background: Toxoplasma gondii is a leading cause of severe foodborne illness in first world countries and the most common cause of posterior uveitis. Neither a standard treatment protocol has been established so far, nor has the efficacy of the mostly applied medications and their combinations be proven in well-designed clinical trials. Atovaquone, a hydroxy-1,4-naphtoquinone, is a safe and effective treatment against tachyzoites and cyst forms of Toxoplasma, but it is only FDA and EMEA approved for the treatment of pneumocystis infections. We have started using Atovaquone in ocular toxoplasmosis on a regular, off-label basis in 1996.
Methods: We report about the use of Atovaquone 750 mg twice daily in punctate outer retinal toxoplamosis as well as in Toxoplasma retinochoroiditis resistant to four different antibiotics.
Results: Toxoplasma activity stopped within three weeks of Atovaquone therapy without any side-effects. Conclusions: In our hands the three-week Atovaquone treatment is a safe and efficient therapeutic option in ocular toxoplasmosis. Placebo-controlled randomized trials of anti-Toxoplasma treatment in patients presenting with Toxoplasma retinochoroiditis are required. These trials should include Atovaquone.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version